Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
Francisco Espejo‐Porras, Laura García‐Toscano, Carmen Rodríguez‐Cueto, et al.
British Journal of Pharmacology (2018) Vol. 176, Iss. 10, pp. 1585-1600
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

New Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases
Eveljn Scarian, Camilla Viola, Francesca Dragoni, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2698-2698
Open Access | Times Cited: 49
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system
Marta Aymerich, Ester Aso, Miguel Angel Abellanas, et al.
Biochemical Pharmacology (2018) Vol. 157, pp. 67-84
Open Access | Times Cited: 96
The cannabinoid system and microglia in health and disease
Samuel S. Duffy, Jessica P. Hayes, Nathan T. Fiore, et al.
Neuropharmacology (2021) Vol. 190, pp. 108555-108555
Closed Access | Times Cited: 71
Oligodendrocyte Dysfunction in Amyotrophic Lateral Sclerosis: Mechanisms and Therapeutic Perspectives
Stefano Raffaele, Marta Boccazzi, Marta Fumagalli
Cells (2021) Vol. 10, Iss. 3, pp. 565-565
Open Access | Times Cited: 62
New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders
Berhanu Geresu Kibret, Hiroki Ishiguro, Yasue Horiuchi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 975-975
Open Access | Times Cited: 46
CB2 receptor in the CNS: From immune and neuronal modulation to behavior
Wanda Grabon, Sylvain Rheims, Jonathon Smith, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 150, pp. 105226-105226
Open Access | Times Cited: 28
An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives
Xiuli Wang, Huanbang Zhang, Yan Liu, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106810-106810
Closed Access | Times Cited: 27
Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists
Miroslav Kosar, Roman C. Sarott, David A. Sykes, et al.
ACS Central Science (2024) Vol. 10, Iss. 5, pp. 956-968
Open Access | Times Cited: 9
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment
Loreto Martínez-González, Carmen Rodríguez‐Cueto, Diego Cabezudo, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 55
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Xiaojiao Xu, Dingding Shen, Yining Gao, et al.
Translational Neurodegeneration (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 45
Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells
Ana Bernal‐Chico, Vanja Tepavčević, Andrea Manterola, et al.
Glia (2022) Vol. 71, Iss. 1, pp. 103-126
Open Access | Times Cited: 29
Cannabinoid CB2 Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimer’s Disease
Samuel Ruiz de Martı́n Esteban, Irene Benito‐Cuesta, Itziar Terradillos, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 29
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
Carmen Rodríguez‐Cueto, Irene Santos‐García, Laura García‐Toscano, et al.
Biochemical Pharmacology (2018) Vol. 157, pp. 217-226
Closed Access | Times Cited: 52
Oxidative Stress as a Therapeutic Target in Amyotrophic Lateral Sclerosis: Opportunities and Limitations
Hee Ra Park, Eun Jin Yang
Diagnostics (2021) Vol. 11, Iss. 9, pp. 1546-1546
Open Access | Times Cited: 34
Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice
Claudia Gonzalo‐Consuegra, Irene Santos‐García, Laura García‐Toscano, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116473-116473
Open Access | Times Cited: 6
Amyotrophic Lateral Sclerosis and Pain: A Narrative Review from Pain Assessment to Therapy
Vincenzo Pota, Pasquale Sansone, Sara De Sarno, et al.
Behavioural Neurology (2024) Vol. 2024, pp. 1-23
Open Access | Times Cited: 5
Cannabinoid CB2 Receptor Modulation by the Transcription Factor NRF2 is Specific in Microglial Cells
Marcos Galán-Ganga, R. del Río, Natalia Jiménez-Moreno, et al.
Cellular and Molecular Neurobiology (2019) Vol. 40, Iss. 1, pp. 167-177
Open Access | Times Cited: 39
Targeting TDP‐43 proteinopathy with drugs and drug‐like small molecules
Emanuele Buratti
British Journal of Pharmacology (2020) Vol. 178, Iss. 6, pp. 1298-1315
Open Access | Times Cited: 35
Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders
Hiroki Ishiguro, Berhanu Geresu Kibret, Yasue Horiuchi, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 20
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Marcos Galán-Ganga, Carmen Rodríguez‐Cueto, Jesús Merchán‐Rubira, et al.
Acta Neuropathologica Communications (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 27
Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential
Valeria Gasperi, Tatiana Guzzo, Alessandra Topai, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 12, pp. 1420-1457
Closed Access | Times Cited: 18
Endocannabinoid signaling in glioma
Carlos Costas‐Insua, Manuel Guzmán
Glia (2022) Vol. 71, Iss. 1, pp. 127-138
Open Access | Times Cited: 17
Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential
Barbara Vuić, Tina Milos, Lucija Tudor, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3000-3000
Open Access | Times Cited: 17
Exploring the 1,3-benzoxazine chemotype for cannabinoid receptor 2 as a promising anti-cancer therapeutic
Nicola Gambacorta, Valeria Gasperi, Tatiana Guzzo, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115647-115647
Closed Access | Times Cited: 10
Amyotrophic Lateral Sclerosis, the Endocannabinoid System, and Exogenous Cannabinoids: Current State and Clinical Implications
Travis T. Denton, Gregory T. Carter, Moses Goddard, et al.
Muscle & Nerve (2025)
Closed Access
Page 1 - Next Page

Scroll to top